Glucose and Fat Metabolism in Acromegaly: From Mice Models to Patient Care.
Patients with active acromegaly are frequently insulin resistant, glucose intolerant, and at risk for developing overt type 2 diabetes. At the same time, these patients have a relatively lean phenotype associated with mobilization and oxidation of free fatty acids. These features are reversed by curative surgical removal of the growth hormone (GH)-producing adenoma. Mouse models of acromegaly share many of these characteristics, including a lean phenotype and proneness to type 2 diabetes. There are, however, also species differences with respect to oxidation rates of glucose and fat as well as the specific mechanisms underlying GH-induced insulin resistance. The impact of acromegaly treatment on insulin sensitivity and glucose tolerance depends on the treatment modality (e.g. somatostatin analogs also suppress insulin secretion, whereas the GH antagonist restores insulin sensitivity). The interplay between animal research and clinical studies has proven useful in the field of acromegaly and should be continued in order to understand the metabolic actions of GH.
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Jakob
J
Dal
Edward O
EO
List
Jens Otto L
JO
Jørgensen
Darlene E
DE
Berryman
D000172:Acromegaly / Q000378:metabolism*; D000818:Animals; D005947:Glucose / Q000378:metabolism*; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D050356:Lipid Metabolism / Q000502:physiology*; D051379:Mice; D005791:Patient Care; D013004:Somatostatin / Q000031:analogs & derivatives
D013004:Somatostatin; D013006:Growth Hormone; D005947:Glucose